Regrowth Concentration Zero (RC0) as Complementary Endpoint Parameter to Evaluate Compound Candidates During Preclinical Drug Development for Cancer Treatment

doi:10.4172/1948-5956.13 Copyright: © 2009 Avramidis D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The screening process for potential anticancer drugs in-volves expensive and time consuming preclinical and clini-cal trials (CT) before a drug is approved for clinical use (CU). At present, there is a “bottleneck ” at the CT/CU transition because many drugs that showed promising re-sults during preclinical research did not pass clinical tri-als. We speculated that the endpoint parameters (the in-hibitory concentration 50 (IC50) or lethal concentration 100 (CL100)) commonly used in proliferation assays fo